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A B S T R A C T

The prevalence of takotsubo cardiomyopathy (TCM) has been on the rise, but co-occurrence with hypertrophic cardiomyopathy (HOCM) remains rare. Although presenting patient demographics were similar to those
in TCM, the potential for hemodynamic compromise was signiﬁcantly compounded by the presence of
underlying HOCM. Management was similar to standalone TCM, although use of inotropic agents and
mechanical support appears to be more prevalent. Despite the increased potential for complications and the
paucity of data regarding management, outcomes appear to be mostly favorable in both the hospitalization
period and at follow-up. Interestingly, despite a new diagnosis of HOCM in about half the cases described,
which signiﬁes no signiﬁcant left ventricular outﬂow tract (LVOT) gradient prior to TCM, half of those
patients had a persistently elevated LVOT gradient after resolution of TCM. This poses a question of whether
or not TCM can predispose to LVOT obstruction in HOCM patients even after its resolution.
© 2020 Elsevier Inc. All rights reserved.

Introduction
Hypertrophic obstructive cardiomyopathy (HOCM) and takotsubo cardiomyopathy (TCM) are two distinct myocardial disease
entities that rarely coexist.1 HOCM is the most common genetic
cardiomyopathy and the most common cause of sudden cardiac
death, yet there is an overwhelming lack of high-level evidence
regarding the approach to its work-up and management.2 Takotsubo cardiomyopathy is a newer entity however, ﬁrst described
in the late 20th century in Japan,3 where its name was derived
from the Japanese word for “octopus trap” which it resembles in
appearance in its most classical form.4 Contrary to HOCM, it is an
acquired condition most commonly affecting postmenopausal
women who suffer a severe psychological or physical stressor,
although cases without an identiﬁed precipitating stressor have
been reported.5
While the approach to either entity as separate conditions is common practice, treating both entities occurring together may be a challenge to healthcare providers. The lack of guidelines in managing
these patients is likely related to the rarity of this occurrence. Herein
* Corresponding author.
E-mail addresses: M.hamdyy@live.com, Mohammed.AbozenahMD@baystatehealth.
org (M. Abozenah).

we present a systematic review of the literature describing 18 cases
of TCM overlapping with HOCM. We aim to identify patterns that
may be suggestive of their coexistence on initial presentation, as well
as clues to delineate severity of illness prior to decompensation.
Additionally, we aim at providing potential management approaches
in treating this rare entity.

Methods
A combination of the following search terms was used to identify
articles in the PubMed/Scopus databases up until August 2019: takotsubo cardiomyopathy (including the hyphenated version tako-tsubo),
stress cardiomyopathy, broken heart, and hypertrophic cardiomyopathy. The bibliographies of identiﬁed manuscripts were also utilized.
A total of 47 records were identiﬁed with the described search terms
in the English literature. Of them, 20 were excluded after identiﬁcation as cohort studies, commentaries, letters or editorials. Twentyseven remaining records were identiﬁed as case reports. Of these, 17
manuscripts that describe cases identifying takotsubo cardiomyopathy and hypertrophic obstructive cardiomyopathy were included.
Case reports identifying sigmoid hypertrophy were excluded. Fig. 1
represents a PRISMA ﬂowchart showing study screening and selection process.

https://doi.org/10.1016/j.hrtlng.2020.10.006
0147-9563/© 2020 Elsevier Inc. All rights reserved.
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Fig. 1. PRISMA ﬂowchart showing study screening and selection process.

Results
Seventeen records, comprising a total of eighteen cases, were
identiﬁed to describe coexisting takotsubo and hypertrophic cardiomyopathies, the majority occurring during or after 2011 (Table 1).
The majority of the patients described were females (77.8%), with the
median age of the cases described being 66.2 years. Half of the
patients outlined had a known history of hypertrophic cardiomyopathy (50%). One third of the patients described had known hypertension prior to presentation (33%), whereas known ischemic cardiac
disease was rare (11%). Report of home medications was not uniform
across all cases described, however, of those reported on, betablocker therapy was the most common (39%), followed by cibenzoline (11%) and calcium channel blockers (6%) (Table 1).
Chest pain was the commonest presenting complaint (72%), followed by shortness of breath (39%). Of the 11 cases with documented
hemodynamic status, the majority were normotensive (55%), but
almost half presented in or developed shock (45%) during their hospital course, despite only 36% being noted to be tachycardic. Though 7
cases did not have documented hemodynamic parameters, it is
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assumed that these patients did not have shock which brings the
prevalence of shock in the cases described down to 28%. A new murmur was identiﬁed in half of the cases presented (50%), with 22% of
patients found to be in volume overload on exam. Electrocardiogram
changes were common in all patients, with ST-segment elevation
and T-wave inversions occurring most frequently (50% each). Troponin elevation was noted on laboratory work-up in 100% of reported
levels (83% of all patients). All cases presented displayed apical akinesis demonstrated on either echocardiography or left ventriculography. In the absence of angiographically signiﬁcant coronary artery
disease this would be the classic diagnostic ﬁnding of the most common subtype of takotsubo cardiomyopathy, the apical variant. This
was used as the diagnostic criteria for takotsubo cardiomyopathy in
the cases presented. Echocardiography revealed a reduced left ventricular ejection fraction in 82% of cases with a reported ejection fraction, whereas systolic anterior motion of the mitral valve (SAM)
occurred 67% of the time and mitral regurgitation was identiﬁed in
44% of cases. All cases, but one, with documented mitral regurgitation
also had SAM (88%). The majority of patients had documented elevation of the left ventricular outﬂow tract (LVOT) pressure gradient on
echocardiography or left ventriculography (78%). Atrial ﬁbrillation
with rapid ventricular response developed in three patients (17%)
during their hospital course, two of which had associated cardiogenic
shock. Causality between atrial ﬁbrillation and shock was able to be
demonstrated in both cases, as the patients were hemodynamically
stable prior to onset of atrial ﬁbrillation with rapid ventricular
response, and there was a lack of evidence for other sources of
shock.6,7
Medical management was most commonly implemented, noted
in 78% of cases. Thirty-nine percent of patients were managed in an
intensive care unit setting with the remainder of cases managed on
general medical or step-down ﬂoors, although that is not entirely
clear. The most common medical management was in the form of
beta-blocker therapy (72%), and 92% of patients who received betablockers did so via the oral, versus intravenous, route. Other common
medications utilized included angiotensin converting enzyme (ACE)
inhibitors (28%) and diuretics (22%). All patients presenting with
hypotension/shock required brief vasopressor support (28% of all
cases). Calcium channel blocker and antiarrhythmic use was not common (6% and 17%, respectively). Short-term mechanical support was
rarely indicated (11% for intra-aortic balloon pump and 6% for extracorporeal membrane oxygenation). Interventional and surgical management was also rarely utilized on initial presentation, with transcatheter alcohol septal ablation and surgical septal myectomy
utilized in one patient each (6% each).
Outcomes were mostly favorable, and the majority of patients
improved with management as outlined above (94%) with only one
death occurring (6%) due to non-cardiac causes. No mechanical cardiac complications occurred in any of the patients described. At follow-up, less than half the patients (44%) had a persistent LVOT
pressure gradient either at rest or with provocation (by exercise or
dobutamine), however, only a fraction of those patients were symptomatic (25%). Both symptomatic patients with a persistent LVOT
pressure gradient subsequently underwent transcatheter alcohol
septal ablation, with resultant improvement in pressure gradient and
symptoms afterwards (Table 2). Of those with a persistent LVOT pressure gradient at follow-up, 63% had a preserved LVEF whereas the
remainder of patients had no reported LVEF at follow-up.
Discussion
Our study reveals several trends and outcomes across all cited
cases. Patients presenting with concomitant HOCM and TCM do not
signiﬁcantly differ in demographics or comorbidities compared to
TCM alone, which is expected given that the acute presentation
mostly pertains to TCM rather than HOCM. Medical management
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Table 1
Summary of cases reporting on patients diagnosed with TCM and HOCM.
Age and
Gender

Past Medical History

Presenting
symptoms

Physical Exam

Blood work

EKG

Coronary
angiogram

Left
Ventriculography

Akita et al.30

66 F

HOCM on bisoprolol
and cibenzoline

Presyncope

Arakawa
et al.16

62 F

None

Chest pain, syncope in the setting of
emotional stress

Hypotension and
grade 4/6 systolic murmur at
the apex

Troponin I level
1.53 ng/mL

ST-segment elevation in I, aVL and
V3-V6

Normal coronaries

Akinesis of apical,
anteroapical,
and inferoapical
walls. MR and
hyperdynamic
function of the
basal segments
of the LV. On
pullback, a 50mmHg gradient
was noted

SAM; Severe MR

Benavides
et al.31

67 F

Asymmetric septal
hypertrophic
cardiomyopathy

Atypical chest pain
in the setting of
emotional stress

Grade 3/6 systolic
ejection murmur at the left
second intercostal space. S4
heart sound.

Troponin I level
1.7 ng/mL

Normal sinus
rhythm with ST
segment elevations in the precordial leads

Normal coronaries

Apical ballooning

Reduced left ventricular ejection
fraction of 35%
with anteroseptal and apical
akinesis, with
systolic anterior
motion of the
mitral valve
causing a left
ventricular outﬂow tract gradient of
35 mm Hg

Brabham
et al.32

48 M

Hyperlipidemia

Persistent, sharp,
left-sided chest
pain, shortness
of breath, and
diaphoresis

Grade 2/6 systolic
murmur at right
upper sternal
border

CKMB 6.25 ng/ml
(normal
4.9 ng/ml) and
Troponin I
1.14 ng/ml (normal 0.06 ng/
ml)

Q waves in V1 V2
and 1 2 mm of
ST elevation in
V2 V4

Mild luminal irregularities in all
coronaries

Severe hypokinesis
of the apical,
anterior apical,
and inferior apical walls with
hyperdynamic
function of the
base

Asymmetric septal
hypertrophy.
Akinesis of the
distal anterior,
distal septal,
distal inferior,
distal lateral,
and apical walls.

New negative T
wave in leads
V1 3

Echocardiogram
ﬁndings

Course

Outcome

SAM of the mitral
valve, and
increasing
severity of
mitral regurgitation, with left
ventricular outﬂow tract
(LVOT) gradient
at 109 mmHg

Echocardiography
and cardiac MRI
1 month later
showed wall
motion abnormality had
resolved and the
LVOT gradient
decreased, but
was still signiﬁcant. NYHA III
dyspnea and
fatigue persisted
due to an insufﬁcient dose of
bisoprolol and
cibenzoline
(doses could not
be increased
due to side
effects)
On day 13, dobutamine stress
echo showed a
dynamic LVOT
gradient of
250 mmHg with
a late peaking
developed during stress, which
was accompanied by severe
MR due to SAM.
Endomyocardial
biopsy of the
right ventricular
septum showed
hypertrophied
and bizarre
myocytes with
myocyte
disarray
Uncomplicated
hospital course,
discharged
3 days later

Percutaneous
transluminal
septal myocardial ablation
was performed.
Repeat echocardiogram
showed a postprocedural
LVOT gradient
of 3 mmHg. Systolic anterior
motion was
absent, mitral
regurgitation
decreased, and
basal obstruction
disappeared.

Admitted to the
cardiac ICU,
uncomplicated
hospital course,
discharged
3 days later

Discharged on
Bisoprolol
2.5 mg daily.
NYHA Class I

Follow-up echocardiogram
2 weeks later
demonstrated
an ejection fraction of 65% and
systolic anterior
motion of the
mitral valve
with no change
in the previously reported
left ventricular
outﬂow tract
gradient
Discharged on
beta-blocker,
angiotensinconverting
enzyme inhibitor, statin, aspirin. One year
later presented

(continued on next page)
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Case

70 F

67 M

66 M

Smoking,

Elhosseiny et
al.28

Gordon
et al.33

65 F

Age and
Gender

Daralmmori
et al.1

Case

Table 1 (Continued)

hypertension

HOCM, hypertension

HOCM, hypertension,
dyslipidemia, and
coronary heart disease with stents in
the left anterior
descending artery
and left circumﬂex.
Noncompliant with
home medications.

Hypertension

Past Medical History

Chest tightness,
shortness of
breath

Syncope, polyuria,
polydipsia,
nausea

Chest pain

Sudden onset
shortness of
breath

Presenting
symptoms

Troponin 13.8 ng/
mL

Cardiac markers
cited as
"positive"

_

Troponin 1.5 ng/
mL (normal: <
0.05)

Troponin I
increased from
2.04 ng/mL to
5.89 ng/mL (normal range
0 0.15 ng/mL)

Blood work

Irregularly irregular heart rate

Harsh systolic
murmur over
left sternal
border

Normal

Physical Exam

Anterolateral, apical, and inferoapical dyskinesis and basal
anterior and
basal inferior
wall hyperkinesis; ejection
fraction (EF)
was 20%

Asymmetric septal
wall thickening,
LVOT gradient
40 mmHg, SAM
of mitral leaﬂet,
severe MR

Normal coronaries

Mild coronary
artery disease

Atrial ﬁbrillation
with rapid ventricular
response as well
as ST elevations
in leads II, III,
aVF, and V3 V6

T-wave inversions
in leads II, III,
aVF, V3-V6

_

Typical apical ballooning with a
globally reduced
ejection fraction
estimated at
35%

Left
Ventriculography

Non-obstructive
coronary artery
disease, patent
stents, and an
intracavitary
gradient of
50 mmHg on
pullback

Mild atherosclerotic coronary
artery disease,
but no signiﬁcant stenosis

Coronary
angiogram

T wave inversions
from V3 to V5
on admission

ST-elevation in the
precordial leads
from V2 to V4

EKG

Hyperkinesis of
the ventricle at
the base, akinesis at the apex,
severe MR and
an overall picture of apical
ballooning. On
pullback, a gradient of

EF 43%. SAM and
mid-systolic
notching of the
aortic valve.
LVOT Doppler
revealed a peak
gradient of
96 mmHg,
increasing to
105 mmHg with
the Valsalva
maneuver
LV septal wall
thickness of
24 mm, and systolic anterior
motion (SAM) of
the anterior
mitral valve
leaﬂet. Peak systolic pressure
gradient below
the level of aortic valve of
20 mmHg at
rest, increasing
to 70 mmHg
after Valsalva
maneuver
Normal ejection
fraction with
severe hypokinesis of the apical wall.
Dynamic
obstruction during Valsalva in
the outﬂow
tract, peak
velocity of
613 cm/s and an
estimated peak
gradient of
150 mmHg
Apical hypokinesis; EF was
35 40%

Echocardiogram
ﬁndings
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A repeat echocardiogram 5 days
after the surgery
documented the
disappearance
of the LVOT gradient and MR
and a signiﬁcant
improvement in
LV apical wall
motion

Repeat echocardiogram on day 5
showed documented resolution of apical
ballooning. EF
improved to
45%

One month later,
repeat echocardiogram
showed a normal ejection
fraction with a
resolution of the
apical hypokinesis and an exercise-induced
LVOT of 80 mm
Hg

3 months later, the
patient was
asymptomatic
whereas transthoracic echocardiography
continued to
show the same
gradient of
50 mmHg across
the LVOT

with progressive
exertional dyspnea, chest pain,
and presyncope.
Underwent
alcohol ablation
of the proximal
septum through
the ﬁrst septal
perforator

Outcome

(continued on next page)

HgbA1c of 11.8
later revealed a
new diagnosis
of diabetes mellitus. DKA was
controlled by
day 4 of hospital
stay. Atrial
ﬁbrillation was
rate controlled
with carvedilol
and diltiazem
Underwent septal
myomectomy

Started on Metoprolol succinate
daily

Discharged on
medical treatment including
beta blocker,
statins, and low
dose aspirin

Course

M. Abozenah et al. / Heart & Lung 50 (2021) 546 557
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81 F

84 F

49 M

Ochiumi
et al.36

Patrianakos
et al.37

54 F

Modi et al.34

Nalluri et al.35

Age and
Gender

Case

Table 1 (Continued)

HOCM, alcohol abuse

HOCM

HOCM s/p ICD placement (due to syncopal episodes),
paroxysmal atrial
ﬁbrillation, pulmonary embolism, lung
cancer, GI bleed

Motor neuron disease

Past Medical History

Chest pain

Chest pain

Shortness of
breath at rest
associated with
mild substernal
chest pressure
and one episode
of non-bloody
vomiting

Chest pain, new
systolic murmur
and
hypotension

Presenting
symptoms

Grade II/VI systolic
murmur at the
left parasternal
border

_

Bilateral rales, a
harsh systolic
crescendodecrescendo
murmur along
the left lower
sternal border,
and a grade 2
lower extremity
pitting edema

_

Physical Exam

Troponin I elevation 2.5 ng/ml

_

Troponin I 1.26 ng/
mL (normal
<0.05 ng/mL),
CK-MB 13.3 ng/
mL (normal
<6.3 ng/mL),
BNP 3472 pg/mL
(normal <99 pg/
mL)

Troponin T elevated at 0.37
mcg/L

Blood work

New ST-T segment
elevation in
leads V3 6

Negative T waves
in leads I, aVL,
and V1-V6 leads

Sinus tachycardia
with intermittent ventricular
pacing with new
ST-T wave
abnormalities in
anterolateral
leads

Anterolateral T
wave inversion

EKG

Normal coronaries

No signiﬁcant coronary stenosis

No signiﬁcant CAD

A muscle bridge in
the mid-left
anterior
descending
artery, apical
ballooning and
mitral incompetence. Left ventricle to aorta
pullback gradient was 25 mm
Hg

Coronary
angiogram

Apical ballooning
with basal
hyperkinesis
and low ejection
fraction

Apical ballooning
with excessive
contractions at
the base of the
heart. Left ventricular outﬂow
pressure gradient 100 mmHg
in the mid and
basal portions of
the left ventricle

_

_

Left
Ventriculography

Asymmetric basal
septal wall
hypertrophy of
18 mm, LV midapical dyskinesia with compensatory basal
hyperkinesis,
SAM of the
mitral valve
with outﬂow
tract, LVOT
obstruction, EF
30%

EF of 20% 25%
(signiﬁcant
hypokinesis of
apical, apical lateral, and apical
septal walls
with a hyperdynamic basal
inferoseptal and
anterolateral
walls), SAM of
mitral valve
causing a
dynamic LVOTO
(peak gradient
>90 mm Hg),
and severe
mitral regurgitation with a posteriorly directed
jet
_

40 mmHg was
noted
Apical left ventricular ballooning,
hypercontractile
basal regions
and severe functional mitral
regurgitation.
Septal hypertrophy was noted
at 1.9 cm with
SAM of the MV

Echocardiogram
ﬁndings
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Ten days later, follow-up echocardiography
showed normalization of the
wall motion
abnormality and
an improvement
in the left ventricular outﬂow
pressure
gradient
A repeat echocardiogram after
2 days, revealed
normalization of
wall motion and
LVEF, resolution
of SAM and
LVOT obstruction and reappearance of the
midventricular
obstruction at
the level of papillary muscles
with velocities
up to 2.5 m/s

Following withdrawal of the
IABP and inotropes, hemodynamic parameters and mitral
regurgitation
improved significantly but she
died 3 days later
due to pneumonia and motor
neuron disease
related respiratory muscle
weakness
Over a period of
three days, her
condition
improved.
Weaned off the
phenylephrine
drip and
switched to oral
amiodarone.
Repeat echo day
5 showed an EF
74% with mild
hypokinesis of
the apical and
apical septal
walls, and peak
LVOT gradient
was reduced to
22 mm Hg.

Outcome

(continued on next page)

Started on metoprolol 100 mg
twice per day

_

Hospital course
complicated by
cardiogenic
shock with
worsened
congestive heart
failure and atrial
ﬁbrillation with
rapid ventricular response. she
was started on
phenylephrine
and amiodarone
infusion

Due to profound
hypotension,
adrenaline and
dobutamine
were commenced and
IABP inserted.
MV replacement
was deemed
unsuitable due
to her history of
advanced motor
neuron disease

Course
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70 F

HOCM

79 F

81 F

Singh et al.25

43 F

Roy et al.38

Roy et al.38

Age and
Gender

Case

Table 1 (Continued)
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HOCM

Sudden onset shortness
of breath

Stress-induced cardiomyopathy with subsequent resolution,
mild CAD, ongoing
tobacco use, hypertension,
hyperlipidemia

Alcohol abuse, hypertension, previous
tobacco abuse

Past Medical History

Sudden onset
chest pain

Stage II/VI harsh
and late peaking
systolic ejection
murmur at the
fourth left intercostal space

Epigastric and
chest pain that
radiated to her
back and jaw

Confusion, agitation, and shortness of breath

Presenting
symptoms

Troponin T 2.5 ng/
mL

ST segment elevation and the disappearance of
the R wave in
the precordial
leads

Troponin I 8.86 ng/
mL

Apical 3/6 systolic
murmur and

Troponin T level of
0.3 ng/mL and a
CKMB level of
10 ng/mL (normal, <3.8 ng/
mL)

Troponin T level of
0.27 ng/mL
(normal,
<0.03 ng/mL)

Blood work

Mild epigastric
tenderness
without guarding or rebound

Tachycardia, nontender hepatomegaly, and
mild pitting
edema in the
lower
extremities

Physical Exam

Anterolateral wall
ischemia

No signiﬁcant CAD

Sinus tachycardia,
T-wave inversion in the anterolateral leads,
and poor precordial R-wave
progression

Sinus tachycardia
with T-wave
inversions and
nonspeciﬁc STT wave abnormalities in the
anterolateral
leads

EKG

Mild, nonobstructive CAD

Normal coronaries

Coronary
angiogram

Severe mitral
regurgitation,

Dyskinesis of the
apical segment
along with signiﬁcant basal
hyperkinesis
with an LV ejection fraction of
50%. SAM of the
mitral leaﬂet
and mitral
regurgitation.
Pressure gradient at LVOT was
estimated to be
107 mmHg.

Apical ballooning
syndrome

_

Left
Ventriculography

2-month followup visit, the

Discharged from
the hospital on
b-blocker and
angiotensinconverting
enzyme (ACE)
inhibitor therapy. 2 weeks
later, repeat
echo showed
that apical wallmotion abnormalities had
resolved, and
the LVEF had
returned to normal at 69%.
Newly apparent
hypertrophy of
the LV myocardium at the
apex, with additional involvement of the
right ventricular
apex, was consistent with apical-variant HCM
One month later,
repeat echo
revealed an
LVEF of 65%
without regional
wall-motion
abnormalities.
LV apex was
thickened, with
an “ace of
spades” cavity
conﬁguration
that suggested
apical HCM

Outcome

(continued on next page)

She was later stabilized and
started on 5 mg
Bisoprolol daily.
Repeat echo on
day 22 showed
normal LV wall
motion with no
apical ballooning or basal
hyperkinesis.
LVOT peak
velocity signiﬁcantly decreased
as a result of the
disappearance
of basal hyperkinesis and SAM
of the mitral
leaﬂet, with signiﬁcant
improvement in
MR.
Stabilized with
oxygen,
Course complicated by atrial
ﬁbrillation, cardiogenic shock
necessitating
noradrenaline
administration
followed by
cardioversion

Basal hypertro
phied septum,

Discharged from
the hospital
5 days later on
therapy with
aspirin, a
b-blocker, an
ACE inhibitor,
and a statin

On day 6, repeat
echo showed
minimal
improvement in
LVEF and no
change in the
apical ballooning and akinesis

Course

LVEF of 0.39 with
akinesis and
dilation of the
mid and apical
LV segments,
suggesting an
apical variant of
takotsubo
cardiomyopathy

EF 47% with hyperdynamic basal
function.
Dilated, akinetic
apex that suggested an apical
variant of
stress-induced
cardiomyopathy

Echocardiogram
ﬁndings
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78 F

63 F

Vassiliou
et al.24

Age and
Gender

Sossalla
et al.40

Case

Table 1 (Continued)

None

HOCM s/p trans-coronary ablation of septal hypertrophy

Past Medical History

Acute chest pain

Acute dyspnea and
anginal chest
pain

Presenting
symptoms

Ejection systolic
murmur at the
left parasternal
border

pulmonary
edema

Physical Exam

_

Elevated Troponin
(level not
speciﬁed)

Blood work

Anterior precordial
lead ST-segment
elevation

EKG

Normal coronaries

No obstruction of
the coronary
arteries

No obstruction of
the coronary
arteries

Coronary
angiogram

Basal hyperkinesis
with apical akinesis consistent
with takotsubo
cardiomyopathy
and moderate
mitral
regurgitation

Apical ballooning
with septal
hyperkinesis

anteroapical
ballooning, and
basal hyperkinesis with an EF
25%

Left
Ventriculography

Severe refractory
cardiogenic
shock with renal
and hepatic failure prompting
urgent VAECMO with an
inability to be
weaned off,
requiring bailout trans-coronary alcohol
ablation of septal hypertrophy;
VA-ECMO
weaned off
1 day after septal ablation and
she was discharged on
guideline-recommended
medications for
systolic heart
failure
Pulmonary edema
and incipient
cardiogenic
shock, which
responded to
treatment with
a combination
of intravenous
diuretics and
intravenous
esmolol
Sever mitral regurgitation, systolic
anterior motion
of the mitral
valve, and LVOT
obstruction
with a peak gradient of 120
mmHg

LVOT obstruction
due to systolic
anterior motion
of the mitral
valve and moderate mitral
regurgitation

diuretics, and
b-blockers, and
she was discharged from
the hospital on
the 4th day

Course

resting LVOT
obstruction ~
20 mmHg,
severe mitral
valve regurgita
tion, and apical
akinesis

Echocardiogram
ﬁndings

3 months later,
ECG changes
resolved and an
MRI scan
showed LV function had normalized. Continued evidence of
signiﬁcant left
ventricular
hypertrophy
and dynamic
obstruction following lowdose dobutamine, consistent with
hypertrophic
cardiomyopathy

apical ballooning had
completely
resolved (LVEF,
0.65), and the
dynamic LVOT
obstruction was
relatively less
severe
Follow-up at 8
weeks revealed
no limiting
heart failure
symptoms and a
good quality of
life; Echo
showed an EF of
55% with mildmoderate mitral
regurgitation
and no signiﬁcant LVOT
gradient

Outcome
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Table 2
Grouped characteristics and outcomes identiﬁed across cases.
N = 18 cases; mean age: 66.2 years; males 22.2%, females 77.8%
Comorbidities
Hypertrophic Obstructive Cardiomyopathy
Hypertension
Hyperlipidemia
Coronary artery disease
Home medication [4 cases with no report of home medication)
Beta-blocker
Calcium channel blocker
Cibenzoline
Presenting symptoms
Chest pain
Shortness of breath/dyspnea
Hemodynamic status (7 cases without documented vital signs)
Tachycardia
Hypotension/Shock
Exam ﬁndings (5 cases without documented physical exam)
Murmur
Volume overload
Troponin elevation
EKG changes (1 case without reported EKG ﬁndings)
ST elevations
T-wave inversion
Non-speciﬁc EKG changes
Coronary angiogram
LV ventriculogram
Systolic anterior motion of mitral valve on echocardiogram
Mitral regurgitation on echocardiogram
Reduced ejection fraction on echocardiogram or LV ventriculogram
Elevated rest or provoked LV outﬂow tract gradient on echocardiogram or LV
ventriculogram
Medical management [2 cases without reported management]
Beta-blocker
Calcium channel blocker
Angiotensin converting enzyme inhibitor
Diuretic
Antiarrhythmics (Amiodarone, Cibenzoline)
vasopressors
In-patient mechanical support
Intra-aortic balloon pump (IABP)
Extra-Corporeal Membrane Oxygenation (ECMO-VA)
Transcatheter alcohol IV septal ablation
Surgical IV septal myectomy
Death

with beta-blocker therapy was most common, with other interventional/surgical procedures a rarity. While guidelines in managing
these cases are nonexistent and management may be challenging,
outcomes appear favorable with only a single identiﬁed death in our
review.
Hypertrophic cardiomyopathy is a hereditary disease of heart
muscle cells, and is by far the most common genetic cardiomyopathy,
or heart muscle disease. First described in the medical literature as
far back as 1868 by Vulpian, its current nomenclature only emerged
in the mid 1900s after English pathologist Robert Donald Teare
reported autopsy ﬁndings of 8 patients with asymmetric cardiac
hypertrophy in 1957.6 HOCM is known to result in LVOT obstruction
in the setting of reduced cardiac preload and/or tachycardia, predisposing to cardiogenic shock and sudden death. This classically is presented as a case of sudden death in an athlete during strenuous
physical exertion. Though generally thought of as a cardiomyopathy
of the young, HOCM may be asymptomatic for decades, with the initial diagnosis occurring during middle age or beyond.7-9 Diagnosis is
usually achieved using Doppler echocardiography, although rarely
more advanced diagnostic studies such as cardiac MRI are needed.
Management comprises avoidance of preload reduction, implantation of automated cardiac deﬁbrillators in certain settings, septal
ablation therapy or myectomy, and ultimately cardiac
transplantation.7,10

N (%)

10 (56)
6 (33)
3 (17)
2 (11)
7 (39); 2 non-compliant
1 (6)
2 (11)
13 (72)
7 (39)
4 (22)
5 (28)
9 (50)
4 (22)
15 (83) [3 remaining cases with no report of troponin levels]
9 (50)
9 (50)
1 (6)
17 (94)
14 (78) [3 cases with no report on LV ventriculogram]
12 (67) [1 case with no echocardiogram ﬁndings reported)
8 (44)
9 (50) [7 cases with no comment on EF; including the case without an echocardiogram report]
14 (78)

13 (72) [12 oral and 2 intravenous]
1 (6)
5 (28)
4 (22)
3 (17)
5 (28)
2 (11)
1 (6)
1 (6)
1 (6)
1 (6)

Takotsubo cardiomyopathy, on the other hand, is an acquired condition affecting heart musculature as a result of stress.11 Since its ﬁrst
description in Japan, TCM has been increasingly recognized, in large
part due to more readily available cardiac catheterization as well as a
better deﬁnition of the syndrome in the literature. Its pathogenesis
remains unclear despite multiple proposed theories including, but
not limited to, catecholamine surge, LVOT obstruction with compensatory basal hyperkinesia, impaired coronary microcirculation, and
multivessel coronary spasm.11 Diagnosis requires ruling out obstructive coronary artery disease followed by utilizing cardioprotective
medications for management pending resolution of myocardial dysfunction over time as the disease follows its natural course, generally
to complete resolution within 8 weeks.
Presenting features
In the reported cases, the presenting symptoms of TCM in patients
with underlying HOCM was not different from that in patients without HOCM. The concurrent presence of both entities can lead to
angina, low cardiac output, shortness of breath, syncope, and exertional dyspnea. In our study, 72% and 39% presented with chest pain
and shortness of breath respectively, with pre-syncope/syncope also
described in 11%. LVOT obstruction is commonly reported in 10 33%
of patients presenting with TCM, with rates as high as 50% previously
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reported.12-19 In HOCM, LVOT obstruction is more prevalent, with
33% of patients reported to have LVOT obstruction at rest and another
33% with physiological provocation, such as with exercise.20 Interestingly, our ﬁndings showed an elevated LVOT gradient in 78% of
patients, a more pronounced rate compared to either as a stand-alone
entity. This is also important to consider when viewing rates of persistent LVOT obstruction at follow-up. Additionally, our review
showed an incidence of cardiogenic shock in 28% of patients as compared to less than 10% in patients with TCM alone.21 From this we
can infer that hypotension and shock are likely to occur more frequently with both entities than in those with TCM alone. We hypothesize that this is potentially related to the increased rates of LVOT
obstruction, though this statement cannot be made conclusively in
the absence of an analysis to conﬁrm it. Although TCM may sometimes mask underlying HOCM, given discovery of HOCM in some
cases described here occurred only after resolution of TCM, a patient
presenting with TCM and cardiogenic shock should raise suspicion
for an underlying HOCM.
Management
The management of both entities together can be challenging.
Patients presenting with TCM are commonly managed similarly to
patients in acute decompensated heart failure. Diagnosis comprises
ruling out acute coronary syndrome via diagnostic cardiac catheterization [29850871], with management focusing on cardiac protective
therapy using negative inotropy with beta-blockers, vasodilators,
diuretics and vasopressor agents when shock ensues.3 However, the
presence of concomitant HOCM and TCM may render such therapeutic strategies contraindicated. Careful phenotype proﬁling and continuous monitoring are warranted in such rare cases. Treatment
primarily revolves around resolution of the LVOT obstruction, which
is commonly achieved with supportive care and the use of betablockers and ﬂuid resuscitation. Unlike hypotension related to LV
dysfunction, care must be taken not to use inotropic agents in the
treatment of hypotension/shock related to LVOT obstruction given
the likely dynamic nature of the obstruction and decreased ventricular ﬁlling with beta-receptor agonism will decrease left ventricular
diameter and worsen the degree of obstruction.15,22 If severe LVOT
obstruction and hypotension preclude the use of beta blocker therapy, alpha-receptor agonists may be used with caution. Pure alpha
-receptor agonists like phenylephrine may reduce the LVOT gradient
by increasing afterload and improving hemodynamics. Beta-blockers
can later be slowly added to reduce inotropy and basal hyperkinesis
as patients enter the recovery phase. The optimal use of vasopressor
agents is speculative and based solely on our understanding of the
pathophysiology of HOCM and TCM as stand-alone entities, hence a
recommendation regarding optimal vasopressor therapy cannot be
made conclusively, but alpha-receptor agonists might be the preferential agents for the reasons outlined above.
Antiarrhythmics routinely used to manage HOCM patients in the
outpatient setting, such as cibenzoline,23 do not appear to serve an
important role in the acute in-patient management of the patients
described. However, management of arrhythmias (particularly atrial
ﬁbrillation with rapid ventricular response) is beneﬁcial, be it using a
rate-control or a rhythm-control strategy.20 Patients with volume
overload should undergo diuresis slowly and cautiously to avoid precipitation of LVOT obstruction which could result in obstructive cardiogenic shock. Intravenous ﬂuid resuscitation may be warranted in
patients not in volume overload on initial presentation and may serve
to prevent or slow down progressive worsening of LVOT obstruction,
particularly in those with borderline low blood pressures. Given the
increased risk of complications that can be seen in this patient population, most notably cardiogenic shock, it is prudent to have the cardiology service involved as soon as coexisting HOCM and TCM is
identiﬁed. Management on a cardiac step-down ﬂoor or in an

intensive care setting may also prove beneﬁcial. In the cases
reviewed, only 20% of patients in cardiogenic shock requiring vasopressor support received an alpha-selective agent, while 60%
received agents that synergize both alpha- and beta-adrenergic
receptors and 20% received non-adrenergic vasopressors with action
primarily on the peripheral vasculature (vasopressin). Most patients
described did not present in volume overload. In patients receiving
diuresis, most tolerated it well, however, diuresis might have predisposed the patient described by Daralammori et al. to develop an elevated pressure gradient across the LVOT.1
The features of TCM are expected to be reversed with time and
appropriate medical therapy. As such, continued surveillance with
echocardiography may be necessary to monitor disease progression.
If symptoms are not adequately controlled, follow-up with structural
cardiology specialists may be warranted to determine if any procedure for HOCM may be necessary to further lower the LVOT gradient
and relieve symptoms. Outcomes appear favorable when managing
this rare occurrence. Only 1 non-cardiac death was described in the
cases we report. Most patients had favorable outcomes at follow-up
as well, as evidenced by the lack of persistent LVOT PG on follow-up
in more than half of all cases, per results from rest or stress echocardiography in most instances. Time to resolution of LVOT PG is uncertain given the great variability in follow-up intervals in the cases
described, although most follow-up was commonly performed
within 4 weeks of discharge. Additionally, of those with persistent
LVOT PG at follow-up (44%) only 25% were symptomatic and required
deﬁnitive invasive management of HOCM. Interestingly, of the
patients with a new diagnosis of HOCM at the time of hospitalization,
38% had an elevated LVOT PG at follow-up. Given the fact that those
with a new diagnosis of HOCM were asymptomatic previously likely
due to a normal LVOT PG, it would be expected that their PG normalizes after resolution of the acute TCM. Persistence of elevated PG after
TCM resolution in HOCM patients who were previously asymptomatic poses the question of whether a history of TCM increases the risk
of developing a newly elevated LVOT PG in HOCM patients, even after
resolution of TCM (Fig. 2 represents a proposed management algorithm for patients diagnosed with TCM and HOCM).
Coincidence or causality?
Whether patients with known HOCM have a predisposition to
TCM is currently unclear. Several potential mechanisms may relate
the two entities. A catecholamine surge may result in increased wall
stress and exacerbate resting LVOT gradient, resulting in increased
intraventricular pressure, apical wall stress and subendocardial
ischemia, leading to the phenomenon of TCM.24 Additionally, baseline decreased coronary reserve and systolic coronary squeezing in
HOCM may predispose to wall-motion abnormalities in the setting of
increased wall stress related to a sympathetic surge.25-27 Trigger
identiﬁcation in the cases we present revealed that 61% of cases
described had a known preceding physical or psychosocial trigger,
which is similar to the frequency of identiﬁed preceding trigger in
TCM alone (about 70%). In cases without a reported trigger however,
it is possible that TCM occurred in the setting of worsening LVOT
obstruction secondary to HOCM, particularly as evidenced by the
case described by Elhosseiny et al. who reports TCM occurring in a
patient with HOCM after exercise in the setting of medication noncompliance.28
A statement regarding whether or not developing TCM worsens
underlying HOCM-associated LVOT obstruction/gradient cannot be
conclusively made either using the data provided. Although it is possible that developing TCM might have predisposed HOCM patients to
developing a new or worsening elevated LVOT PG, this conclusion is
speculative at this point given lack of pre-hospitalization LVOT PG for
most patients precluding a more certain statement regarding this.
The theory is that the previously undiagnosed HOCM patients likely
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Fig. 2. Management algorithm for patients diagnosed with TCM and HOCM.

had a normal LVOT PG prior to hospitalization with HOCM given
likely lack of symptoms, meaning that the 44% of them who had persistently elevated LVOT PG at follow-up likely had that as a new ﬁnding following TCM onset and resolution.
Limitations
The utilization of case reports imparts a potential selection bias of
rather unusual and unique presentations of concomitant HOCM and
TCM. The true prevalence of this entity is unknown and difﬁcult to
deduce solely from reported cases. More stable patients are less likely

to be reported on and outcomes are possibly more favorable with
fewer complications. Additionally, there is a high likelihood of missing the diagnosis of underlying HOCM in more stable patients, which
might only be diagnosed at a later date after resolution of TCM and
the acute presentation. Alternatively, it is equally possible that severe
cases of coexisting HOCM and TCM might have been missed if those
cases progressed to demise rapidly, prior to adequate diagnostic
work-up. Furthermore, the variability in data reporting coupled with
the small sample size made it not feasible to run an analysis on the
data for identiﬁcation of patterns or associations with important outcomes such as shock development and persistence of LVOT
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obstruction at follow-up. Additional limitations included lack in uniformity of follow-up intervals, as well as inconsistencies in the testing
performed at follow-up. Time to recovery is also difﬁcult to gauge
given the variability in follow-up intervals.
Conclusion
With advanced cardiovascular testing becoming more readily
available, the prevalence of both HOCM and TCM is likely to continue
to rise. Currently there exists no guidelines or data to guide the management of these cardiomyopathies when they coexist, posing a challenge to physicians. Since the ﬁrst case describing both entities
occurring together was reported in 2006,29 numerous other cases
have been reported. From the available reported cases, certain trends
and management options can be deduced. Although the patients
described in our study share similar characteristics with those presenting in TCM without underlying HOCM, they have a higher potential for decompensation. Presenting features are primarily chest pain
and shortness of breath, secondary to the symptoms of TCM. Patients
with underlying HOCM presenting with TCM had a higher prevalence
of LVOT obstruction compared to either entity alone. Additionally,
these patients were at a higher risk of developing cardiogenic shock
as compared to those in TCM without underlying HOCM. Care should
be taken in managing such patients with a potential for rapid decompensation of their hemodynamic parameters in the setting of slight
changes in preload and/or afterload. Volume status should be monitored closely, and diuresis in the setting of volume overload should
be undertaken cautiously, preferably under step-down or critical care
level surveillance. Beta-blockade remains the cornerstone of medical
management in this patient population, with cardiogenic shock preferentially managed using alpha-adrenoceptor agonism in an attempt
at increasing afterload and reducing LVOT gradient, and as a result,
LVOT obstruction. Similarly, intravenous ﬂuid resuscitation may be
warranted in patients not in volume overload, serving to reduce
LVOT obstruction. Further prospective studies are needed to establish
safe management guidelines in dealing with this rare and challenging
presentation.
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